AlfaroCLMcClureRKVertreesJEBenavidesR. Unanticipated plasma concentrations in two clozapine-treated patients. Ann Pharmacother2001; 35: 1028–31.
2.
OlesenOVLinnetK. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high contributions. J Clin Pharmacol2001; 41: 823–32.
3.
BenderSEapCB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry1998; 55: 1048–50.
4.
LuMLLaneHYChenKPJannMWSuMHChangWH. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry2000; 61: 594–9.
5.
OlesenOVLinnetK. Fluvoxamine—clozapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol2000; 20: 35–42.
6.
WetzelHAnghelescuISzegediAWiesnerJWeigmannHHärtterS. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol1998; 18: 2–9.
7.
MauriMCRudelliRBravinSGianettiSGiulianiEGuerriniA. Clozapine metabolism rate as a possible index of drug-induced granulocytopenia. Psychopharmacology1998; 137: 341–4.
8.
PerryPJMillerDDArndtSVCadoretRJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry1991; 148: 231–5.
LaneHYChangWH. Clozapine versus risperidone in treatment-refractory schizophrenia: Possible impact of dosing strategies. J Clin Psychiatry1999; 60: 487–8.
